Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

Learn more about:
Related Clinical Trial
Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

Official Title

Lipoatrophy in Children, Adolescents and Adults With Modern Treatment Modalities: is There a Beneficial Effect of Insulin Glulisine?

Brief Summary

      The purpose of this study is to investigate whether a zinc-free insulin is an effective
      treatment option for lipoatrophy in patients with type 1 Diabetes (T1D) and insulin pump
      (CSII, continuous subcutaneous insulin infusion) therapy.

Detailed Description

      Randomized, controlled, open-label parallel study. Clinical Study Phase IV After being
      included in the study, subjects are getting an extensive dermatological examination by a
      pediatric dermatologist familiar with cutaneous complications of T1D, additionally
      pathological results will be documented by photography and, if necessary, videodermoscopy.
      Additionally, an evaluation of their lipoatrophic areas using imaging methods like ultrasound
      (USG) and MRI will be performed. After randomization, half of the included children switch
      their pump insulin into insulin glulisine (intervention group) for 6 months. The others
      continue their current treatment (control group) and switch to insulin glulisine 6 months
      later. Both groups are followed-up until month 12. Hence, after the 4th visit at 6 months,
      all enrolled patients are on insulin glulisine pumps for a further period of 6 months.

Study Phase

Phase 4

Study Type


Primary Outcome

Relative thickness as assessed by MRI

Secondary Outcome

 Relative thickness as assessed by MRI


Type 1 Diabetes



Study Arms / Comparison Groups

 Group 1
Description:  Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2016

Completion Date

April 2019

Primary Completion Date

April 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with type 1 diabetes and documented lipoatrophy at injection sites on CSII

          -  Age between 6 and 40 years (both inclusive, see rationale for the inclusion of minors

          -  Signed informed consent form from patients or from parents/their guardians if
             children/youths <18 years

          -  Patients must be willing to undergo all study procedures

        Exclusion Criteria:

          -  Patients with previous use of insulin glulisine

          -  Patients requiring corticosteroids as treatment medication. NOTE inhaled
             corticosteroids are allowed.

          -  Patients suffering from severe chronic disease other than T1D or genetic disorder
             (i.e. Down syndrome etc.)

          -  Pregnant or lactating women

          -  Patients participating in other device or drug studies

          -  History of drug or alcohol abuse within the last five years prior to screening

          -  Anamnestic history of hypersensitivity to the study drugs (or any component of the
             study drug) or to drugs with similar chemical structures

          -  History of severe or multiple allergies

          -  Treatment with any other investigational drug within 3 months prior to screening

          -  Progressive fatal disease

          -  History of significant cardiovascular (such as myocardial infarction, stroke, TIA),
             respiratory, gastrointestinal, hepatic (ALT and/or AST > 3 times the normal reference
             range), renal (creatinine > 1.1 mg/dl in women and > 1.5 mg/dl in men), neurological,
             psychiatric and/or hematological disease as judged by the investigator

          -  Sexually active women of childbearing potential not consistently and correctly
             practicing birth control by implants, injectables, combined oral contraceptives,
             hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner

          -  Lack of compliance or other similar reason that, according to investigator, precludes
             satisfactory participation in the study

          -  Prisoners or subjects who are involuntarily incarcerated

        Target Disease Exclusions

          -  History of T2DM, maturity onset diabetes of young (MODY), pancreatic surgery or
             chronic pancreatitis

          -  Any use of oral hypoglycemic agents within 12 months prior to the screening visit

          -  History of diabetes ketoacidosis (DKA) within 12 weeks prior to the screening visit

          -  History of hospital admission for glycemic control (either hyperglycemia or
             hypoglycemia) within 3 months prior to the screening visit

          -  Frequent episodes of hypoglycemia as defined by more than one episode requiring
             assistance, emergency care (paramedics or emergency room care) or glucagon therapy, or
             more than 2 unexplained episodes of symptomatic hypoglycemia within 3 months prior to
             the screening visit. An unexplained event is defined as an event that cannot be
             explained by circumstances such as dietary (e.g. missed meal), strenuous exercise,
             error in insulin dosing, etc.

          -  Hypoglycemic unawareness

          -  History of diabetes insipidus

          -  History of Addison's disease or chronic adrenal insufficiency

        Physical and Laboratory Test Findings

          -  BMI above 35 kg/m2

          -  RR > 180/110 mm Hg

          -  Aspartate aminotransferase (AST) > 3X Upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) > 3X ULN

          -  Serum total bilirubin > 3X ULN

          -  Estimated GFR (eGFR) < 60 ml/min/1.73 m2

          -  Hemoglobin ≤ 11.0 g/dl (110 g/l) for boys / men; hemoglobin ≤10.0 g/dl (100 g/L) for
             girls / women.

          -  Creatine kinase (CK) > 3X ULN

          -  Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody.

          -  Abnormal Free T4 Note: abnormal TSH value at screening will be further evaluated for
             free T4. Subjects with abnormal free T4 values will be excluded. A one-time retest may
             be allowed, as determined by the Investigator, after a minimum of 6 weeks following
             the adjustment of thyroid hormone replacement therapy in subject who have had a prior
             diagnosis of a thyroid disorder and who are currently receiving thyroid replacement
             therapy. Such cases should be discussed with the Investigator prior to retesting.




6 Years - 40 Years

Accepts Healthy Volunteers



Olga Kordonouri, MD, , 

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Kinderkrankenhaus auf der Bult



Study Sponsor

Olga Kordonouri, MD, Principal Investigator, Kinder- und Jugendkrankenhaus AUF DER BULT

Verification Date

October 2019